Table 6 from this paper includes some incorrect data in the ‘Outcome’ rows for DAFNE and EURIDIS. The start of the table, including the corrected information, is shown below:
The authors apologize for this error.
Summary of clinical studies of dronedarone in AF
 |
|
ACS = acute coronary syndrome; ADONIS = American-Australian-African trial with DronedarONe In atrial fibrillation or flutter for the maintenance of Sinus rhythm; AF = atrial fibrillation; ANDROMEDA = ANtiarrhythmic trial with DROnedarone in Moderate to severe heart failure Evaluating morbidity DecreAse; ATHENA = A placebo-controlled, doubleblind, parallel arm Trial to assess the efficacy of dronedarone 400 mg b.i.d. for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter; b.i.d. = bis in die (twice daily); b.p.m. = beats per minute; CI = confidence interval; CV = cardiovascular; DAFNE = Dronedarone Atrial FibrillatioN study after Electrical cardioversion; DIONYSOS = Randomized Double blind trIal to evaluate efficacy and safety of drOnedarone (400 mg b.i.d.) vs. amiodaroNe (600 mg q.d. for 28 daYS, then 200 mg q.d. thereafter) for at least 6 mOnths for the maintenance of Sinus rhythm in patients with atrial fibrillation; EF = ejection fraction; ERATO = Efficacy and safety of dRonedArone for The cOntrol of ventricular rate during atrial fibrillation; EURIDIS = EURopean trial In atrial fibrillation or flutter patients receiving Dronedarone for the maIntenance of Sinus rhythm; MI = myocardial infarction; RRR = relative risk reduction; SE = systemic embolism.
Summary of clinical studies of dronedarone in AF
|
|
ACS = acute coronary syndrome; ADONIS = American-Australian-African trial with DronedarONe In atrial fibrillation or flutter for the maintenance of Sinus rhythm; AF = atrial fibrillation; ANDROMEDA = ANtiarrhythmic trial with DROnedarone in Moderate to severe heart failure Evaluating morbidity DecreAse; ATHENA = A placebo-controlled, doubleblind, parallel arm Trial to assess the efficacy of dronedarone 400 mg b.i.d. for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter; b.i.d. = bis in die (twice daily); b.p.m. = beats per minute; CI = confidence interval; CV = cardiovascular; DAFNE = Dronedarone Atrial FibrillatioN study after Electrical cardioversion; DIONYSOS = Randomized Double blind trIal to evaluate efficacy and safety of drOnedarone (400 mg b.i.d.) vs. amiodaroNe (600 mg q.d. for 28 daYS, then 200 mg q.d. thereafter) for at least 6 mOnths for the maintenance of Sinus rhythm in patients with atrial fibrillation; EF = ejection fraction; ERATO = Efficacy and safety of dRonedArone for The cOntrol of ventricular rate during atrial fibrillation; EURIDIS = EURopean trial In atrial fibrillation or flutter patients receiving Dronedarone for the maIntenance of Sinus rhythm; MI = myocardial infarction; RRR = relative risk reduction; SE = systemic embolism.
